OPKO Health Announces Appointment of David Okrongly, Ph.D. as President of
its Diagnostics Business Unit
MIAMI -- July 16, 2013
OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of David
Okrongly, Ph.D. as president of its diagnostics business unit.
Dr. Okrongly brings to OPKO extensive experience developing and
commercializing advanced diagnostic platforms. Prior to joining OPKO, Dr.
Okrongly most recently served as chief operating officer of Exosome
Diagnostics, Inc. where he was responsible for establishing product, platform
and regulatory strategy for the company’s proprietary technology for purifying
RNA derivatives from exosomes. Prior to this, Dr. Okrongly served as president
and chief executive officer of Quanterix Corporation, leading the company in
development of the first fully automated, single-molecule diagnostic platform
with 1,000 times better sensitivity than ELISA. Dr. Okrongly was with Bayer
Diagnostics, a subsidiary of Bayer AG (ETR: BAYN), for over nine years and led
the unit’s global R&D organization, launching industry-leading platforms in
immunoassay, hematology, clinical chemistry and molecular diagnostics. While
at Bayer Diagnostics, he also served as senior vice president in charge of the
Molecular Diagnostics business unit. Dr. Okrongly received his Bachelors’
degree from the University of Wisconsin-Madison and his Ph.D. from Columbia
University, both in Chemistry.
“David’s profound industry knowledge will be invaluable as we near the U.S.
commercial launch for our 4Kscore™ prostate cancer diagnostic test, advance
the development of our point of care diagnostic platform, and continue to
execute our strategy of establishing industry-leading positions in large and
rapidly growing medical markets,” said Phillip Frost, M.D., Chairman and Chief
Executive Officer of OPKO. “We are extremely pleased to welcome David to
About OPKO Health, Inc.
OPKO is a multi-national biopharmaceutical and diagnostics company that seeks
to establish industry-leading positions in large and rapidly growing medical
markets by leveraging our discovery, development and commercialization
expertise and our novel and proprietary technologies. For more information,
This press release contains "forward-looking statements," as that term is
defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
which statements may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "intends,"
"estimates," and other words of similar meaning, including all non-historical
statements about our expectations, beliefs or intentions regarding our
business, technologies and products, financial condition, strategies,
prospects, growth opportunities, and management. Many factors could cause our
actual activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission, and
risks inherent in funding, developing and obtaining regulatory approvals of
new, commercially-viable and competitive products and treatments. In addition,
forward-looking statements may also be adversely affected by general market
factors, competitive product development, product availability, federal and
state regulations and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements contained in
this press release speak only as of the date the statements were made, and,
except as required by applicable law, we do not undertake any obligation to
update forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
OPKO Health, Inc.
Juan F. Rodriguez, 305-575-4102
Press spacebar to pause and continue. Press esc to stop.